Related Experiment Video
Updated: Jul 8, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Targeted therapies in myelodysplastic syndrome
1Department of Interdisciplinary Oncology, Malignant Hematology Division, Moffitt Cancer Center and Research Institute, Tampa, FL 33611, USA. melcheme@moffitt.usf.edu
Seminars in Hematology
|January 9, 2008
Summary
New treatments for myelodysplastic syndromes (MDS) are emerging, offering hope beyond current FDA-approved therapies. Ongoing research into novel agents aims to expand therapeutic options and combinations for MDS patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Therapeutic options for myelodysplastic syndromes (MDS) remain limited, despite recent advancements.
- Current FDA-approved agents like azacitidine, decitabine, and lenalidomide offer responses but are not curative.
Purpose of the Study:
- To review the expanding landscape of novel therapeutic agents for myelodysplastic syndromes.
- To highlight agents in early clinical development targeting key pathways in myelopoiesis.
Main Methods:
- Review of recent clinical trial data and pharmacologic development in MDS.
- Categorization of novel agents based on their mechanisms of action.
Main Results:
- Multiple novel agents targeting immunomodulation, survival signals, thrombopoiesis, differentiation, and angiogenesis are in development.
- These agents have shown promise in early-phase clinical testing for MDS.
Conclusions:
- The pipeline for MDS therapeutics is expanding with diverse novel agents.
- Future treatment strategies will likely involve novel combinations of these emerging therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...